Literature DB >> 2995600

High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.

S S Legha, I W Dimery.   

Abstract

Nephrotoxicity of cisplatin can be ameliorated with intravenous (IV) hydration and forced diuresis with mannitol. Cisplatin has recently been used with hypertonic saline which allows administration of higher doses amounting to 40 mg/m2/d for 5 days, without significant nephrotoxicity. In this report we describe our experience with administration of cisplatin in a dose range of 30 to 40 mg/m2/d for 5 days, administered with IV hydration alone. Thirteen patients with recurrent carcinoma of the head and neck region were treated with high-dose cisplatin along with 5-fluorouracil (5-FU) used as a continuous infusion. Eight patients received a total of 21 courses of cisplatin with the higher dose range (40 mg/m2 for 5 days) and the remainder received 11 courses with the lower dose range. The renal toxicity was minimal but the myelo-suppression was intense, frequently requiring hospitalization for the treatment of infections associated with neutropenia. Furthermore, we encountered severe peripheral neuropathy in five patients, four of whom developed major difficulties with ambulation. Six patients achieved objective regression of their tumor, two had minor response, and five failed to respond to chemotherapy. The study was terminated because of serious nonrenal toxicity from the high-dose cisplatin. Based on our limited experience, we believe that IV hydration alone, without the use of hypertonic saline, allows administration of high-dose cisplatin without significant nephrotoxicity. However, cisplatin used in a dose schedule of 40 mg/m2 for 5 days for more than three courses resulted in a disabling form of peripheral neuropathy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995600     DOI: 10.1200/JCO.1985.3.10.1373

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

1.  The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.

Authors:  A Hovestadt; M E van der Burg; H B Verbiest; W L van Putten; C J Vecht
Journal:  J Neurol       Date:  1992-03       Impact factor: 4.849

Review 2.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study.

Authors:  S M Grunberg; J J Crowley; R B Livingston; F M Muggia; J S MacDonald; S K Williamson; R L Stephens
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  Evolution of high-dose cisplatin.

Authors:  W M Holleran; M W DeGregorio
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

5.  Progressive paresthesias after cessation of therapy with very high-dose cisplatin.

Authors:  S M Grunberg; S Sonka; L L Stevenson; F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Phase I study of oxaliplatin in patients with advanced cancer.

Authors:  J M Extra; M Espie; F Calvo; C Ferme; L Mignot; M Marty
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

8.  Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.

Authors:  V Gebbia; R Valenza; A Testa; G Zerillo; S Restivo; G Cupido; F Ingria; G Spadafora; C Barbaccia; G Cannata
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

9.  High-dose cisplatin in disseminated melanoma: a comparison of two schedules.

Authors:  J E Mortimer; S Schulman; J S MacDonald; K Kopecky; G Goodman
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.

Authors:  F Di Re; S Bohm; S Oriana; G B Spatti; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.